ALZN Alzamend Neuro, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1677077 · Fiscal year ends 04/30
Financial factors as of 2026-07-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-45.7%
TTM EPS YoY-72.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-163.2%
ROA-122.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets32.1%
Debt / equity0.00x
Current ratio—
Interest coverage-1,480.55x
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-30.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-04-30 | FY20252025-04-30 | FY20242024-04-30 | FY20232023-04-30 | FY20222022-04-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $3.63M | $1.41M | $6.46M | $7.45M | $5.20M |
| SG&A expense | $5.14M | $3.08M | $3.48M | $7.42M | $7.12M |
| Operating income | -$8.77M | -$4.50M | -$9.94M | -$14.87M | -$12.32M |
| Interest expense | $6,619 | $18,029 | $10,101 | $7,701 | $46,524 |
| Pretax income | -$8.77M | -$4.51M | -$9.95M | -$14.88M | -$12.36M |
| Net income | -$8.77M | -$4.51M | -$9.95M | -$14.88M | -$12.36M |
| EBITDA | -$8.66M | -$4.45M | -$9.89M | -$14.85M | -$12.32M |
| EPS (basic) | -2.63 | -11.32 | -132.33 | -22.89 | -0.14 |
| EPS (diluted) | -2.63 | -11.32 | -132.33 | -22.89 | -0.14 |
| Weighted avg. shares (diluted) | 3.34M | 450,799 | 74,174 | 650,126 | 89.10M |
| Balance sheet | |||||
| Cash & equivalents | $710,689 | $3.95M | $376,048 | $5.14M | $14.06M |
| Current assets | $1.76M | $4.18M | $455,242 | $5.84M | $14.41M |
| PP&E, net | $314,866 | $425,606 | $176,346 | $79,843 | $102,909 |
| Total assets | $2.08M | $4.60M | $631,588 | $5.92M | $14.52M |
| Current liabilities | — | — | — | $2.87M | $1.16M |
| Total liabilities | $1.35M | $634,761 | $3.23M | $2.87M | $1.16M |
| Shareholders' equity | $733,211 | $3.97M | -$2.59M | $3.05M | $13.35M |
| Shares outstanding | 4.26M | 778,733 | 76,444 | 646,267 | 95.48M |
| Cash flow statement | |||||
| Operating cash flow | -$8.07M | -$6.57M | -$8.27M | -$8.92M | -$6.61M |
| Investing cash flow | — | -$300,000 | -$147,243 | — | -$106,458 |
| Financing cash flow | $4.83M | $10.44M | $3.65M | $200 | $18.85M |
| Depreciation & amortization | $110,740 | $50,740 | $50,740 | $23,066 | $3,549 |
| Stock-based compensation | $707,527 | $325,108 | $955,633 | $3.58M | $4.41M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.